Third Rock Ventures is a leading healthcare venture firm that discovers, launches, and builds innovative companies to develop transformative medicines. The firm partners with scientists, entrepreneurs, and executives to advance promising science into medicines that benefit patients and their families.

We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives. 

THE THIRD ROCK TEAM
Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed. 

A FORMULA FOR INNOVATION 
We only invest in the best of those ideas. We are actively involved in the early stages of our companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence.

We believe in the companies we launch and make big initial investments, often complemented by strategic alliances, to enable our companies to advance life-changing therapies, devices and diagnostics. By creating value for patients, we create value for our investors.

Bluebird Bio

Global Blood Therapeutics

Blueprint Medicines

Kala Pharmaceuticals

Magenta Therapeutics

Voyager Therapeutics

Larimar Therapeutics

Tango Therapeutics

Thrive Earlier Detection

Nurix Therapeutics

Revolution Medicines

Rhythm Pharmaceuticals

Constellation Pharmaceuticals

CytomX Therapeutics

Editas Medicine

Foundation Medicine

Fulcrum Therapeutics

SAGE Therapeutics

Pliant Therapeutics

Relay Therapeutics

Third Rock Ventures

We are delighted to announce the expansion of our senior team. Congratulations to Jigar Raythatha on his promotion to partner as well as Vyas Ramanan on his promotion to Venture Partner. Additionally, a big welcome to Mary Lynne Hedley, Steven Paul (welcome back!), & Courtney Wallace.
https://lnkd.in/eXk_MadE

Congratulations to Synnovation Therapeutics on their launch with a $102 million Series A. We are excited to be a part of the efforts towards improving the care of cancer patients with a pipeline built around highly validated precision oncologic targets.

Today, Rapport is pleased to announce the appointment of Terry-Ann Burrell to our Board of Directors.
 
Terry-Ann, who currently serves as CFO of Beam Therapeutics, has extensive experience in executive financial leadership. Prior to Beam, she was with J.P. Morgan for over a decade covering the biotechnology and pharmaceutical sectors and where she helped to execute a number of major financings. We welcome her to the Board!
 
Read more in today’s release: https://lnkd.in/eiXg5beF

We are excited to see this new collaboration between MOMA Therapeutics and Roche and look forward to continued advancement of MOMA’s KnowledgeBase platform.

Rapport Therapeutics and CARGO Therapeutics were named to BioSpace “NextGen Class of 2024: Top Life Sciences Startups to Watch this Year”. Congratulations to both! We look forward to their continued progress towards changing the lives of patients.

“Giving back is fundamental to our core values at Third Rock.” Tune in to Life Science Cares Boston new podcast #MovingForwardGivingBack to hear more from our own Abbie Celniker.

Congrats to the team at bluebird bio! Exciting news for patients and their families.

COM:THIRDROCKVENTURES

Third Rock Ventures

Analysis Not Available